Tubulis
Tubulis generates uniquely matched protein-drug conjugates by combining proprietary novel technologies with disease-specific biology. The goal of the company is to expand the therapeutic potential of antibody drug conjugates (ADCs) ushering in a new era and delivering better outcomes for patients, especially for the treatment of hematological malignancies.